BR112022026580A2 - Composições e métodos para induzir uma resposta imune contra coronavírus - Google Patents

Composições e métodos para induzir uma resposta imune contra coronavírus

Info

Publication number
BR112022026580A2
BR112022026580A2 BR112022026580A BR112022026580A BR112022026580A2 BR 112022026580 A2 BR112022026580 A2 BR 112022026580A2 BR 112022026580 A BR112022026580 A BR 112022026580A BR 112022026580 A BR112022026580 A BR 112022026580A BR 112022026580 A2 BR112022026580 A2 BR 112022026580A2
Authority
BR
Brazil
Prior art keywords
coronavirus
immune response
methods
induce
compositions
Prior art date
Application number
BR112022026580A
Other languages
English (en)
Inventor
P Steinbuck Martin
M Seenappa Lochana
C Demuth Peter
M Haqq Christopher
mcneil Lisa
Original Assignee
Elicio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicio Therapeutics Inc filed Critical Elicio Therapeutics Inc
Publication of BR112022026580A2 publication Critical patent/BR112022026580A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA INDUZIR UMA RESPOSTA IMUNE CONTRA CORONAVÍRUS. São descritos aqui CpG-anfifílicos e antígenos do coronavírus (por exemplo, uma proteína spike do coronavírus, um peptídeo da mesma ou uma sequência de ácido nucleico que codifica o mesmo) para uso na indução de uma resposta imune em um indivíduo e métodos de administração de CpG-anfifílicos e antígenos do coronavírus (por exemplo, uma proteína spike do coronavírus, um peptídeo da mesma, uma proteína do nucleocapsídeo do coronavírus, um peptídeo da mesma ou uma sequên-cia de ácido nucleico que codifica a mesma) para induzir uma resposta imune em um indivíduo.
BR112022026580A 2020-06-26 2021-06-25 Composições e métodos para induzir uma resposta imune contra coronavírus BR112022026580A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063044773P 2020-06-26 2020-06-26
US202063064836P 2020-08-12 2020-08-12
US202063124200P 2020-12-11 2020-12-11
US202163145200P 2021-02-03 2021-02-03
PCT/US2021/039134 WO2021263131A1 (en) 2020-06-26 2021-06-25 Compositions and methods for inducing an immune response against coronavirus

Publications (1)

Publication Number Publication Date
BR112022026580A2 true BR112022026580A2 (pt) 2023-01-24

Family

ID=79281915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026580A BR112022026580A2 (pt) 2020-06-26 2021-06-25 Composições e métodos para induzir uma resposta imune contra coronavírus

Country Status (9)

Country Link
US (1) US20230263882A1 (pt)
EP (1) EP4171574A1 (pt)
JP (1) JP2023532290A (pt)
KR (1) KR20230044404A (pt)
AU (1) AU2021294342A1 (pt)
BR (1) BR112022026580A2 (pt)
CA (1) CA3183735A1 (pt)
MX (1) MX2023000041A (pt)
WO (1) WO2021263131A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157344A2 (en) * 2020-08-31 2023-04-05 CureVac SE Multivalent nucleic acid based coronavirus vaccines
WO2023159081A2 (en) * 2022-02-15 2023-08-24 Ohio State Innovation Foundation Nanotechnology based intranasal vaccine for covid-19
CN114752631B (zh) * 2022-06-15 2022-09-02 中国人民解放军军事科学院军事医学研究院 Rna及包含其的新型冠状病毒疫苗和制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108937A1 (en) * 2003-06-04 2004-12-16 Bioleaders Corporation Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
EP2833918B1 (en) * 2012-04-05 2019-05-08 Massachusetts Institute of Technology Immunostimulatory compositions and methods of use thereof
KR20200140265A (ko) * 2018-03-02 2020-12-15 엘리시오 테라퓨틱스, 인크. Cpg 양친매성 물질 및 이의 용도

Also Published As

Publication number Publication date
WO2021263131A1 (en) 2021-12-30
AU2021294342A1 (en) 2023-02-23
KR20230044404A (ko) 2023-04-04
MX2023000041A (es) 2023-03-10
CA3183735A1 (en) 2021-12-30
EP4171574A1 (en) 2023-05-03
JP2023532290A (ja) 2023-07-27
US20230263882A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
BR112022019781A2 (pt) Vacina para o coronavírus
CL2021000636A1 (es) Vacuna contra el virus de la peste porcina africana
BR112022015628A2 (pt) Vacina de sars-cov-2
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
BR122019013216B8 (pt) ensaio imunológico para análise de uma vacina contra influenza
BR112022022456A2 (pt) Proteínas de ligação de repetição de anquirina e seus usos
BR112021026439A2 (pt) Vacina para febre suína africana
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
AR056133A1 (es) Virus de influenza canina y composiciones relacionadas y metodos de uso
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
BR112022016580A2 (pt) Composições e métodos para induzir uma resposta imune
WO2023094713A3 (en) Coronavirus vaccine
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
CO2021014778A2 (es) Subunidad s1 modificada de la proteína de espícula de coronavirus
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
MX2019014674A (es) Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones.
MX2022012251A (es) Vacuna universal contra la influenza usando arnm modificado con nucleósidos.